| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 330.52 | 46.0% |
| Total Income | 330.52 | 46.0% |
| Expenditure | 372.37 | 64.4% |
| PBT | 343.17 | 189.5% |
| Net Profit | 330.96 | 174.0% |
| OPM | 100.00% | 149.12pp |
| NPM | 100.00% | 173.18pp |
| EPS | 3.15 | 168.5% |
Sarepta Therapeutics Reports Q1 2026 Financial Results
07 May 2026 · 7 May, 1:48 am
Summary
Sarepta Therapeutics reported financial results for the first quarter 2026, with total revenues of $730.8 million. Net product revenues reached $330.5 million, driven by ELEVIDYS and PMO products. The company achieved GAAP operating income of $358.4 million and is advancing its siRNA pipeline with encouraging early signals. Sarepta has reiterated its FY 2026 revenue guidance of $1.2 - $1.4 billion.
Key Highlights
- 1
Sarepta Therapeutics' net product revenues for the first quarter 2026 totaled $330.5 million, including $102.0 million from ELEVIDYS and $228.6 million from PMO products.
- 2
The company achieved GAAP operating income of $358.4 million and non-GAAP operating income of $397.7 million for the first quarter 2026.
- 3
Sarepta's siRNA pipeline delivered first Phase 1/2 data for SRP-1001 (FSHD1) and SRP-1003 (DM1), showing dose-dependent drug exposure and favorable tolerability.
- 4
The company completed the submission of sNDA for AMONDYS 45 and VYONDYS 53 to the FDA, seeking conversion to traditional approval.
- 5
Sarepta earned a $40.0 million milestone payment following the commercial launch of ELEVIDYS in Japan by Chugai Pharmaceuticals.
- 6
The company reiterates FY 2026 guidance with total net product revenues of $1.2 - $1.4 billion and combined non-GAAP R&D and SG&A expenses of $800.0 - $900.0 million.
- 7
Total revenues were $730.8 million for the three months ended March 31, 2026.
Management Comments
Doug Ingram
"We entered 2026 with clear priorities—stabilizing the business, restoring growth, maintaining financial strength, and advancing a pipeline that we believe can define Sarepta’s next era. In the first quarter, we made meaningful progress against each,” said Doug Ingram, chief executive officer, Sarepta Therapeutics. “Our commercial portfolio has begun to stabilize, supported by expanded field engagement and a growing body of evidence reinforcing the disease‑modifying impact of ELEVIDYS, which we believe is positioned to return to growth. At the same time, we are advancing Cohort 8 of the ENDEAVOR study with sirolimus pretreatment to serve our goal of once again making ELEVIDYS available to the non‑ambulatory community. Finally, we remain in a position of financial strength, with positive earnings, and continued cash flow generation that enables us to fully fund our pipeline. Our potentially best‑in‑class clinical‑stage siRNA portfolio continues to advance, with encouraging early signals in DM1 and FSHD and multiple upcoming readouts across high‑value programs.”
Informational and educational content only. Not investment advice.